TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) and Fonar (NASDAQ:FONR – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends and profitability.
Profitability
This table compares TriSalus Life Sciences and Fonar’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TriSalus Life Sciences | -60.85% | N/A | -69.91% |
| Fonar | 6.35% | 4.12% | 3.07% |
Risk and Volatility
TriSalus Life Sciences has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Fonar has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TriSalus Life Sciences | 1 | 1 | 2 | 0 | 2.25 |
| Fonar | 0 | 1 | 0 | 0 | 2.00 |
TriSalus Life Sciences presently has a consensus target price of $7.50, indicating a potential upside of 111.27%. Given TriSalus Life Sciences’ stronger consensus rating and higher probable upside, equities analysts plainly believe TriSalus Life Sciences is more favorable than Fonar.
Insider and Institutional Ownership
2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 50.6% of Fonar shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 7.9% of Fonar shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares TriSalus Life Sciences and Fonar”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TriSalus Life Sciences | $45.15 million | 4.83 | -$39.23 million | ($1.41) | -2.52 |
| Fonar | $105.34 million | 1.12 | $8.33 million | $1.00 | 19.09 |
Fonar has higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks.
Summary
Fonar beats TriSalus Life Sciences on 9 of the 14 factors compared between the two stocks.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
About Fonar
FONAR Corporation, together with its subsidiaries, engages in the research, development, production, and marketing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company operates in two segments, Medical Equipment, and Physician Management and Diagnostic Services. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company also offers non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with compliance matters, and development and implementation of practice growth and marketing strategies. It owns and operates diagnostic imaging facilities in Florida; and manages MRI scanning facilities. The company markets its scanners to private diagnostic imaging centers and hospital outpatient imaging facilities. FONAR Corporation was founded in 1970 and is based in Melville, New York.
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
